Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 12, 2025
Machine learning-derived serum protein signatures as biomarkers for checkpoint inhibition in melanoma
Katrin Schaper-Gerhardt, Nina Flatt, Uzair Rana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2024
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
Katrin Schaper-Gerhardt, Ralf Gutzmer, Yenny Angela, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 6, 2024
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG
Corinna Kochanek, Catharina Gilde, Lisa Zimmer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 1, 2026
Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centers
Nina Flatt, Corinna Kochanek, Yenny Angela, et al.
The British Journal of Dermatology
|
July 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trial
Jürgen C Becker, Anja H Gesierich, Ulrike Leiter, et al.
The Journal of Pathology. Clinical Research
|
January 16, 2026
Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitors
Viola K DeTemple, Rudolf Stadler, Sabine Bredemeier, et al.
Journal of Cancer Research and Clinical Oncology
|
May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective
Katharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
Viola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Cancers
|
February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
Michael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 12, 2025
Machine learning-derived serum protein signatures as biomarkers for checkpoint inhibition in melanoma
Katrin Schaper-Gerhardt, Nina Flatt, Uzair Rana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2024
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
Katrin Schaper-Gerhardt, Ralf Gutzmer, Yenny Angela, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 6, 2024
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG
Corinna Kochanek, Catharina Gilde, Lisa Zimmer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 1, 2026
Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centers
Nina Flatt, Corinna Kochanek, Yenny Angela, et al.
The British Journal of Dermatology
|
July 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trial
Jürgen C Becker, Anja H Gesierich, Ulrike Leiter, et al.
The Journal of Pathology. Clinical Research
|
January 16, 2026
Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitors
Viola K DeTemple, Rudolf Stadler, Sabine Bredemeier, et al.
Journal of Cancer Research and Clinical Oncology
|
May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective
Katharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
Viola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Cancers
|
February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
Michael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Page
of 4